Literature DB >> 14758773

The proteasome system and proteasome inhibitors in stroke: controlling the inflammatory response.

Mario Di Napoli1, Francesca Papa.   

Abstract

The ubiquitin-proteasome pathway (UPP) is a predominantly non-lysosomal protein degradation pathway responsible for degrading many critical regulatory proteins (e.g., nuclear factor-kappa B). This pathway is widely known for its ubiquitous role in immune and inflammatory responses, control of cell growth and apoptosis. These roles are apparent in the nervous system, but neurons and their neighboring cells also employ the UPP for distinct functions, ranging from development to the co-ordination of cellular responses, injury of the nervous system and brain-specific processes such as aging and memory. Promising results from preclinical studies in animal models indicate that the use of specific proteasome inhibitors to manipulate UPP may prove valuable in treating such conditions as ischemic stroke.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14758773

Source DB:  PubMed          Journal:  Curr Opin Investig Drugs        ISSN: 1472-4472


  10 in total

Review 1.  The ubiquitin-proteasome system as a drug target in cerebrovascular disease: therapeutic potential of proteasome inhibitors.

Authors:  Mario Di Napoli; BethAnn McLaughlin
Journal:  Curr Opin Investig Drugs       Date:  2005-07

2.  Enzyme E2 from Chinese white shrimp inhibits replication of white spot syndrome virus and ubiquitinates its RING domain proteins.

Authors:  An-Jing Chen; Shuai Wang; Xiao-Fan Zhao; Xiao-Qiang Yu; Jin-Xing Wang
Journal:  J Virol       Date:  2011-06-15       Impact factor: 5.103

Review 3.  Inflammation, blood pressure, and stroke: an opportunity to target primary prevention?

Authors:  Mario Di Napoli; Francesca Papa
Journal:  Curr Hypertens Rep       Date:  2005-02       Impact factor: 5.369

4.  IL-35 is a Protective Immunomodulator in Brain Ischemic Injury in Mice.

Authors:  Chen Xu; Hao Zhu; Rong Shen; Qian Feng; Hua Zhou; Zhong Zhao
Journal:  Neurochem Res       Date:  2018-06-08       Impact factor: 3.996

5.  Transformation of the proteasome with age-related macular degeneration.

Authors:  Cheryl M Ethen; Stacy A Hussong; Cavan Reilly; Xiao Feng; Timothy W Olsen; Deborah A Ferrington
Journal:  FEBS Lett       Date:  2007-02-02       Impact factor: 4.124

Review 6.  Proteasome biology and therapeutics in cardiac diseases.

Authors:  Sanket Kumar Shukla; Khadija Rafiq
Journal:  Transl Res       Date:  2018-09-28       Impact factor: 7.012

Review 7.  Cell signalling by reactive lipid species: new concepts and molecular mechanisms.

Authors:  Ashlee Higdon; Anne R Diers; Joo Yeun Oh; Aimee Landar; Victor M Darley-Usmar
Journal:  Biochem J       Date:  2012-03-15       Impact factor: 3.857

8.  Inhibition of Proteasome Activity Upregulates IL-6 Expression in RPE Cells through the Activation of P38 MAPKs.

Authors:  Tingyu Qin; Shasha Gao
Journal:  J Ophthalmol       Date:  2018-07-12       Impact factor: 1.909

Review 9.  TRIM Proteins in Colorectal Cancer: TRIM8 as a Promising Therapeutic Target in Chemo Resistance.

Authors:  Flaviana Marzano; Mariano Francesco Caratozzolo; Graziano Pesole; Elisabetta Sbisà; Apollonia Tullo
Journal:  Biomedicines       Date:  2021-02-27

10.  Peripheral inflammation preceeding ischemia impairs neuronal survival through mechanisms involving miR-127 in aged animals.

Authors:  Sanna Loppi; Paula Korhonen; Maria Bouvy-Liivrand; Simone Caligola; Tiia A Turunen; Mikko P Turunen; Ana Hernandez de Sande; Natalia Kołosowska; Flavia Scoyni; Anna Rosell; Teresa García-Berrocoso; Sighild Lemarchant; Hiramani Dhungana; Joan Montaner; Jari Koistinaho; Katja M Kanninen; Minna U Kaikkonen; Rosalba Giugno; Merja Heinäniemi; Tarja Malm
Journal:  Aging Cell       Date:  2020-12-28       Impact factor: 11.005

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.